AnaptysBio (NASDAQ:ANAB) PT Raised to $45.00 at Guggenheim

AnaptysBio (NASDAQ:ANAB – Get Rating) had its target price hoisted by research analysts at Guggenheim from $44.00 to $45.00 in a research note issued to investors on Friday, The Fly reports. Guggenheim’s price target points to a potential upside of 131.36% from the company’s current price.

ANAB has been the topic of a number of other research reports. JPMorgan Chase & Co. reduced their price target on AnaptysBio from $32.00 to $31.00 and set an “underweight” rating on the stock in a report on Wednesday, April 12th. StockNews.com started coverage on AnaptysBio in a research report on Thursday, March 16th. They issued a “hold” rating on the stock. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $34.83.

AnaptysBio Stock Performance

NASDAQ:ANAB opened at $19.45 on Friday. The firm has a market capitalization of $522.89 million, a price-to-earnings ratio of -4.26 and a beta of -0.16. AnaptysBio has a 52-week low of $18.20 and a 52-week high of $32.44. The stock has a fifty day moving average of $21.77 and a 200 day moving average of $25.30.

AnaptysBio (NASDAQ:ANAB – Get Rating) last released its quarterly earnings results on Wednesday, March 1st. The biotechnology company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.01). AnaptysBio had a negative net margin of 1,251.33% and a negative return on equity of 43.83%. The firm had revenue of $6.81 million for the quarter, compared to analysts’ expectations of $8.20 million. Equities analysts forecast that AnaptysBio will post -4.42 earnings per share for the current fiscal year.

Institutional Investors Weigh In On AnaptysBio

A number of large investors have recently made changes to their positions in the stock. Point72 Asset Management L.P. boosted its holdings in AnaptysBio by 196.6% in the third quarter. Point72 Asset Management L.P. now owns 2,526,200 shares of the biotechnology company’s stock valued at $64,443,000 after purchasing an additional 1,674,400 shares during the last quarter. Braidwell LP purchased a new position in shares of AnaptysBio during the 4th quarter worth approximately $22,503,000. Millennium Management LLC boosted its position in shares of AnaptysBio by 1,050.7% during the 4th quarter. Millennium Management LLC now owns 322,802 shares of the biotechnology company’s stock worth $10,004,000 after purchasing an additional 294,750 shares during the period. State Street Corp lifted its holdings in AnaptysBio by 20.6% during the 2nd quarter. State Street Corp now owns 1,155,881 shares of the biotechnology company’s stock worth $23,464,000 after buying an additional 197,786 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in AnaptysBio by 11.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 891,851 shares of the biotechnology company’s stock worth $22,064,000 after buying an additional 88,457 shares in the last quarter.

About AnaptysBio

(Get Rating)

AnaptysBio, Inc is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro.